论文部分内容阅读
采用两种方法,一种方法是以右旋糖酐(Dextran)和DTPA的二酐为原料,DMAP为催化剂,另一种是以右旋糖酐和DTPA为原料,采用DMAP及EDC.HCl为联合催化剂,合成造影剂Dextran-DTPA-Gd.通过比较产物的水溶性及Gd含量确定了最佳制备条件,得到了钆含量为16.1%、水溶性好的高分子造影剂;通过FTIR、粒度分析表征了Dextran-DTPA-Gd的结构及其分子粒径大小(分布范围为100～150nm,平均值为130nm);动物实验中,以钆喷酸葡胺注射液(Magnevist)为阳性对照,通过对比家兔腿部磁共振成像图,绘制腿部淋巴系统信号增强率-时间曲线,证明Dextran-DTPA-Gd具有更高的信号增强效果(最高值为314%)及淋巴系统选择性的特点,为其进一步应用奠定了基础.
Two methods are used, one is that the dextran (Dextran) and DTPA dianhydride as raw materials, DMAP as the catalyst, the other is dextran and DTPA as raw materials, the use of DMAP and EDC.HCl as a combined catalyst, the synthesis of contrast agent Dextran-DTPA-Gd. The optimal preparation conditions were determined by comparing the water-solubility and Gd content of the product. The high-molecular contrast agent with a gadolinium content of 16.1% and a good water solubility was obtained. Dextran-DTPA-Gd was characterized by FTIR and particle size analysis. Gd structure and molecular size (distribution range of 100 ~ 150nm, with an average of 130nm); animal experiments, with gadopentetate dimeglumine injection (Magnevist) as a positive control, by comparing the rabbit leg magnetic resonance Imaging, rendering the signal enhancement rate of the lymphatic system of the leg - time curve, Dextran-DTPA-Gd proved to have a higher signal enhancement (the highest value of 314%) and lymphatic system selectivity characteristics, and laid the foundation for its further application .